Cargando…
Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study
OBJECTIVES: To investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment. DESIGN AND SETTING: This retrospective cohort study examines publicly reported industry-sponsored events in Austra...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829862/ https://www.ncbi.nlm.nih.gov/pubmed/29440213 http://dx.doi.org/10.1136/bmjopen-2017-019027 |
_version_ | 1783302899647905792 |
---|---|
author | Mintzes, Barbara Swandari, Swestika Fabbri, Alice Grundy, Quinn Moynihan, Ray Bero, Lisa |
author_facet | Mintzes, Barbara Swandari, Swestika Fabbri, Alice Grundy, Quinn Moynihan, Ray Bero, Lisa |
author_sort | Mintzes, Barbara |
collection | PubMed |
description | OBJECTIVES: To investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment. DESIGN AND SETTING: This retrospective cohort study examines publicly reported industry-sponsored events in Australia from October 2011 to September 2015 for three conditions potentially subject to overdiagnosis and overtreatment: depression, osteoporosis and overactive bladder. We used a database of transparency reports to identify events with a focus on depression, osteoporosis and overactive bladder and compared these with other sponsored events. We hypothesised that companies marketing treatments for each condition would sponsor related events and that target audiences would mainly work in primary care, reflecting a broad patient population. MAIN OUTCOME MEASURES: Event and attendee characteristics, sponsoring companies, related marketed treatments, cost-effectiveness ratings and dispensing rates. RESULTS: Over the study period, we identified 1567 events focusing on depression, 1375 on osteoporosis and 190 on overactive bladder (total n=3132, with 96 660 attendees). These events were attended by primary care doctors more often than sponsored events without a focus on these three conditions: relative risk (RR)=3.06 (95% CI 2.81 to 3.32) for depression, RR=1.48 (95% CI 1.41 to 1.55) for osteoporosis and RR=2.59 (95% CI 2.09 to 3.21) for overactive bladder. Servier, which markets agomelatine and AstraZeneca (quetiapine) sponsored 51.2% and 23.0% of depression events, respectively. Amgen and GlaxoSmithKline, which co-market denosumab, sponsored 49.5% of osteoporosis events and Astellas and Commonwealth Serum Laboratories (CSL) (mirabegron and solifenacin) sponsored 80.5% of overactive bladder events. CONCLUSIONS: This 4-year overview of industry-sponsored events on three overdiagnosed and overtreated conditions found that primary care clinicians were often targeted, dinner was often provided and that a few companies sponsored most events. In most cases, sponsors’ products are not cost-effective choices for the specified condition. This pattern highlights the need for professional education to be free of commercial sponsorship. |
format | Online Article Text |
id | pubmed-5829862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58298622018-03-01 Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study Mintzes, Barbara Swandari, Swestika Fabbri, Alice Grundy, Quinn Moynihan, Ray Bero, Lisa BMJ Open Health Policy OBJECTIVES: To investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment. DESIGN AND SETTING: This retrospective cohort study examines publicly reported industry-sponsored events in Australia from October 2011 to September 2015 for three conditions potentially subject to overdiagnosis and overtreatment: depression, osteoporosis and overactive bladder. We used a database of transparency reports to identify events with a focus on depression, osteoporosis and overactive bladder and compared these with other sponsored events. We hypothesised that companies marketing treatments for each condition would sponsor related events and that target audiences would mainly work in primary care, reflecting a broad patient population. MAIN OUTCOME MEASURES: Event and attendee characteristics, sponsoring companies, related marketed treatments, cost-effectiveness ratings and dispensing rates. RESULTS: Over the study period, we identified 1567 events focusing on depression, 1375 on osteoporosis and 190 on overactive bladder (total n=3132, with 96 660 attendees). These events were attended by primary care doctors more often than sponsored events without a focus on these three conditions: relative risk (RR)=3.06 (95% CI 2.81 to 3.32) for depression, RR=1.48 (95% CI 1.41 to 1.55) for osteoporosis and RR=2.59 (95% CI 2.09 to 3.21) for overactive bladder. Servier, which markets agomelatine and AstraZeneca (quetiapine) sponsored 51.2% and 23.0% of depression events, respectively. Amgen and GlaxoSmithKline, which co-market denosumab, sponsored 49.5% of osteoporosis events and Astellas and Commonwealth Serum Laboratories (CSL) (mirabegron and solifenacin) sponsored 80.5% of overactive bladder events. CONCLUSIONS: This 4-year overview of industry-sponsored events on three overdiagnosed and overtreated conditions found that primary care clinicians were often targeted, dinner was often provided and that a few companies sponsored most events. In most cases, sponsors’ products are not cost-effective choices for the specified condition. This pattern highlights the need for professional education to be free of commercial sponsorship. BMJ Publishing Group 2018-02-13 /pmc/articles/PMC5829862/ /pubmed/29440213 http://dx.doi.org/10.1136/bmjopen-2017-019027 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Health Policy Mintzes, Barbara Swandari, Swestika Fabbri, Alice Grundy, Quinn Moynihan, Ray Bero, Lisa Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study |
title | Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study |
title_full | Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study |
title_fullStr | Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study |
title_full_unstemmed | Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study |
title_short | Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study |
title_sort | does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? an australian cohort study |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829862/ https://www.ncbi.nlm.nih.gov/pubmed/29440213 http://dx.doi.org/10.1136/bmjopen-2017-019027 |
work_keys_str_mv | AT mintzesbarbara doesindustrysponsorededucationfosteroverdiagnosisandovertreatmentofdepressionosteoporosisandoveractivebladdersyndromeanaustraliancohortstudy AT swandariswestika doesindustrysponsorededucationfosteroverdiagnosisandovertreatmentofdepressionosteoporosisandoveractivebladdersyndromeanaustraliancohortstudy AT fabbrialice doesindustrysponsorededucationfosteroverdiagnosisandovertreatmentofdepressionosteoporosisandoveractivebladdersyndromeanaustraliancohortstudy AT grundyquinn doesindustrysponsorededucationfosteroverdiagnosisandovertreatmentofdepressionosteoporosisandoveractivebladdersyndromeanaustraliancohortstudy AT moynihanray doesindustrysponsorededucationfosteroverdiagnosisandovertreatmentofdepressionosteoporosisandoveractivebladdersyndromeanaustraliancohortstudy AT berolisa doesindustrysponsorededucationfosteroverdiagnosisandovertreatmentofdepressionosteoporosisandoveractivebladdersyndromeanaustraliancohortstudy |